Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ

Open source

DOI: 10.1038/s41591-024-03266-2
Published: 2024 Dec
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03266-2,
  title = {Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.},
  author = {Khoury K and Meisel JL and Yau C and Rugo HS and Nanda R and Davidian M and Tsiatis B and Chien AJ and Wallace AM and Arora M and Rozenblit M and Hershman DL and Zimmer A and Clark AS and Beckwith H and Elias AD and Stringer-Reasor E and Boughey JC and Nangia C and Vaklavas C and Omene C and Albain KS and Kalinsky KM and Isaacs C and Tseng J and Roussos Torres ET and Thomas B and Thomas A and Sanford A and Balassanian R and Ewing C and Yeung K and Sauder C and Sanft T and Pusztai L and Trivedi MS and Outhaythip A and Li W and Onishi N and Asare AL and Beineke P and Norwood P and Brown-Swigart L and Hirst GL and Matthews JB and Moore B and Fraser Symmans W and Price E and Beedle C and Perlmutter J and Pohlmann P and Shatsky RA and DeMichele A and Yee D and van 't Veer LJ and Hylton NM and Esserman LJ},
  year = {2024},
  journal = {Nature medicine},
  doi = {10.1038/s41591-024-03266-2},
  url = {https://doi.org/10.1038/s41591-024-03266-2}
}

RIS

TY  - JOUR
TI  - Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
AU  - Khoury K
AU  - Meisel JL
AU  - Yau C
AU  - Rugo HS
AU  - Nanda R
AU  - Davidian M
AU  - Tsiatis B
AU  - Chien AJ
AU  - Wallace AM
AU  - Arora M
AU  - Rozenblit M
AU  - Hershman DL
AU  - Zimmer A
AU  - Clark AS
AU  - Beckwith H
AU  - Elias AD
AU  - Stringer-Reasor E
AU  - Boughey JC
AU  - Nangia C
AU  - Vaklavas C
AU  - Omene C
AU  - Albain KS
AU  - Kalinsky KM
AU  - Isaacs C
AU  - Tseng J
AU  - Roussos Torres ET
AU  - Thomas B
AU  - Thomas A
AU  - Sanford A
AU  - Balassanian R
AU  - Ewing C
AU  - Yeung K
AU  - Sauder C
AU  - Sanft T
AU  - Pusztai L
AU  - Trivedi MS
AU  - Outhaythip A
AU  - Li W
AU  - Onishi N
AU  - Asare AL
AU  - Beineke P
AU  - Norwood P
AU  - Brown-Swigart L
AU  - Hirst GL
AU  - Matthews JB
AU  - Moore B
AU  - Fraser Symmans W
AU  - Price E
AU  - Beedle C
AU  - Perlmutter J
AU  - Pohlmann P
AU  - Shatsky RA
AU  - DeMichele A
AU  - Yee D
AU  - van 't Veer LJ
AU  - Hylton NM
AU  - Esserman LJ
PY  - 2024
JO  - Nature medicine
DO  - 10.1038/s41591-024-03266-2
UR  - https://doi.org/10.1038/s41591-024-03266-2
ER  -

APA

K, K., JL, M., C, Y., HS, R., R, N., M, D., B, T., AJ, C., AM, W., M, A., M, R., DL, H., A, Z., AS, C., H, B., AD, E., E, S., JC, B., C, N., C, V., C, O., KS, A., KM, K., C, I., J, T., ET, R. T., B, T., A, T., A, S., R, B., C, E., K, Y., C, S., T, S., L, P., MS, T., A, O., W, L., N, O., AL, A., P, B., P, N., L, B., GL, H., JB, M., B, M., W, F. S., E, P., C, B., J, P., P, P., RA, S., A, D., D, Y., LJ, V. '. V., NM, H., & LJ, E. (2024). Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.. Nature medicine. https://doi.org/10.1038/s41591-024-03266-2

Source records

pubmed · retrieved 2026-09-27T00:17:49.782Z